Eupraxia Pharmaceuticals (EPRX) investor relations material

Market opportunity and disease landscape

• Eosinophilic esophagitis (EoE) is projected to reach 1 million U.S. patients by 2030, with current approved therapies capturing only a small market share.

• EoE is under-recognized, but its prevalence and need for effective long-term treatments are growing.

Product differentiation and clinical development

• The therapy is physician-administered, ensuring compliance and aiming for once-yearly dosing, reducing traditional drug development risks.

• Interim phase II-B data readout is expected in December, including detailed efficacy and safety metrics at multiple time points.

• The phase II-B trial includes a placebo arm, which is critical for validating efficacy and reassuring investors.

Clinical endpoints and data disclosure

• Detailed interim data will cover symptom indices (SDI, DSQ), clinical remission rates, histology, inflammation, fibrosis, and safety.

• Both SDI and DSQ are considered important for regulatory and commercial perspectives, with SDI defining clinical remission.

• Dense biopsy data and primary biopsy site analysis are emphasized for meaningful histological assessment.